SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Genzyme Tissue Repair (GZTR) -- Ignore unavailable to you. Want to Upgrade?

To: BWAC who wrote (2462)1/15/1999 2:23:00 PM
From: KLH  Read Replies (2) | Respond to of 2553
 
Talk about a tortured climb...but you know, they always
say that volume precedes price... and we do have volume.

karl



To: BWAC who wrote (2462)1/15/1999 9:24:00 PM
From: Bobb  Respond to of 2553
 
BWAC,

Thanks. You are right that CLPA could fall to nothing, but so could GZMO. Who ever thought GENZL would lose a 1/5th of its value last year? Anyway, if CLPA has a product that will work on tumor cancers, the $22 price with 25 million shares outstanding will be cheap. If their product is just one more also ran, than $22 is the high. Who knows?

Good luck with GZMO. AND GO GENZL GO!

Bobb


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News